#236 | Is It Time to Rewrite the MedTech Export Commercialisation Playbook?

If so many MedTech companies still struggle to achieve commercial success in export markets, are we asking the right question about why?

MedTech companies have access to more market intelligence, better technology, stronger data and more commercial expertise than ever before. Yet innovative medical devices with regulatory approval, clinical evidence and significant investment can still struggle to achieve meaningful commercial success in export markets. In this episode, Hakeem asks whether the problem is really how well companies execute their commercialisation strategy—or whether it's time to question the playbook itself.

In this episode you'll discover:

Why regulatory approval, clinical evidence and even a great MedTech product don't necessarily translate into commercial success when entering export markets.Why choosing markets, appointing distributors and building sales teams based on assumptions and previous experience can lead to expensive commercialisation mistakes.How starting with the conditions required for customer adoption—and working backwards—can help you build a more systematic MedTech export commercialisation strategy.

Listen now to discover why rethinking the traditional MedTech export commercialisation playbook could help you build a clearer route from regulatory approval to customer adoption and commercial success.

Book a 30min Healthcare Export Accelerator discovery call

Connect with me on Linkedin

This podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.